Skip to main content
. 2019 Jan 24;9(3):505–515. doi: 10.1016/j.apsb.2019.01.010

Figure 4.

Fig. 4

LY294002 reversed SalA-induced cell protective effect, and the AKT and FOXO3a phosphorylation effect in vitro. Cells were pre-treated with LY294002 (10 μmol/L) before OGD/R stimulation and SalA treatment. (A) Effects of LY294002 on the protective effects of SalA by MTT assay. (B) The p-AKT/AKT ratio in SH-SY5Y cells treated without or with LY294002 by Western blot assay. (C) The p-FOXO3a/FOXO3a ratio in SH-SY5Y cells treated without or with LY294002 by Western blot assay. (D) The expression and intracellular localization of FOXO3a (green fluorescence) were assessed by immunofluorescence assay. (E) and (F) The nuclear FOXO3a, cytosolic FOXO3a and BIM levels treated without or with FOXO3a siRNA by Western blot assay. Data was expressed as mean ± SD of 4 independent tests. ##P<0.01 and ###P<0.001 compared with control group, **P<0.01 and ***P<0.001 compared with OGD/R group, ^^^P<0.001 compared with OGD/R+SalA group. Scale bar=20 μm.